Creative Biolabs expands preclinical services for live biotherapeutics

Creative Biolabs said June 23, 2026, that it has expanded an end-to-end preclinical pipeline for live biotherapeutic products and next-generation medical probiotics. The updated CRO offering is designed to move microbiome candidates from discovery through IND-ready safety and efficacy packages.

Why it matters: - Live biotherapeutic products face steep development risks because the microbes must stay viable, scale consistently and avoid safety flags before regulatory review. - Creative Biolabs is positioning an integrated CRO workflow to reduce handoff gaps between discovery, manufacturing and preclinical validation. - The expanded service could help biotech firms, drug developers and academic groups move microbiome candidates faster toward investigational new drug applications.

What happened: - Creative Biolabs announced an expanded preclinical pipeline for live biotherapeutic products and next-generation medical probiotics. - The updated portfolio is designed as an end-to-end solution that connects early discovery work with IND applications. - The company issued the announcement from Shirley, New York, on June 23, 2026.

The details: - The discovery and strain characterization platform covers microbial isolation and screening from environmental and clinical biospecimens. - The workflow uses whole-genome sequencing and 16S rRNA sequencing to classify candidates at the strain level. - Bioinformatics support includes primer and probe design plus carbohydrate fermentative profiling to map metabolic traits. - The bioprocess scale-up and formulation services cover both aerobic and anaerobic culture platforms. - The service set includes cell banking, downstream purification, lyophilization and spray-drying to stabilize live microbes. - Delivery engineering focuses on custom capsule and sachet matrices intended to protect live cells from gastric acid. - The preclinical safety package includes phenotypic and genotypic antimicrobial susceptibility testing to screen for transferable antibiotic resistance genes. - Efficacy work uses in vitro assays such as monocyte activation and immune-modulation testing. - The validation stack also includes in vivo mouse and zebrafish models to examine pharmacokinetics and mechanisms of action. - The company said the workflow is aligned with international regulatory guidelines. - A Technical Director at Creative Biolabs said LBPs face high attrition because viability can drop during manufacturing and immune responses can be hard to verify. - The Technical Director said the integrated workflow is meant to generate reproducible, data-rich packages that de-risk regulatory approval.

Between the lines: - Creative Biolabs is trying to solve a familiar microbiome-development problem: promising strains often fail when discovery, scale-up and safety testing sit in separate pipelines. - The emphasis on strain purity, resistance screening and delivery engineering signals that the company is targeting the most common technical and regulatory blockers, not just early discovery. - The service expansion also suggests growing demand for outsourced preclinical support as more developers pursue live microbial therapeutics.

What's next: - Creative Biolabs said developers can request a tailored technical evaluation. - The company directed interested biotech firms, pharmaceutical developers and academic institutions to its Live Biotherapeutics portal for specifications and expert consultation. - Further progress will likely depend on how effectively the workflow shortens time to IND-ready packages for client programs.

The bottom line: - Creative Biolabs is broadening its CRO platform to cover the full preclinical path for LBPs, aiming to reduce technical failure points before regulatory submission.